Rosuvastatin

Patient

Questions for this perspective

2 drafted questions in this packet. Targeted additions or replacements for the current guide.

patient-05 — How will I know whether it is helping?

Established. Rosuvastatin lowers LDL, a type of cholesterol, by helping your liver remove it from the blood. The change may not make you feel different. A blood test is the way to check whether your LDL changed. The size depends on the dose and your starting level, so compare your result with the goal you made with your care team. Do not stop because one result looks better. Ask when your next test is due.

Sources: Crestor US prescribing information; MedlinePlus: Rosuvastatin

Repair action: retained-and-expanded

patient-18 — Will I need tests or monitoring?

Established. Your care team may check cholesterol after treatment starts or the dose changes. The Crestor label says the full LDL effect is usually seen by 4 weeks. Blood tests may also check liver enzymes when needed. At 40 mg, the label reports more urine protein or blood in some people; tell your clinician if a urine test is abnormal. You may not feel these changes. Ask which tests you need and when, and do not change your dose on your own.

Sources: Crestor US prescribing information; MedlinePlus: Rosuvastatin

Repair action: new-or-replaced-weak-answer

Caregiver

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

caregiver-02 — What changes should I look for?

Established. Rosuvastatin lowers LDL cholesterol through the liver, but the person may feel no change. Keep a short note of the dose, missed doses, new medicines, muscle pain or weakness, dark urine, and test dates. Call the care team about new muscle pain, mainly with fever or feeling very unwell. Bring the medicine bottles or a current list to visits. Do not judge benefit by energy or looks; a blood test checks the cholesterol change.

Sources: Crestor US prescribing information; MedlinePlus: Rosuvastatin

Repair action: new-or-replaced-weak-answer

caregiver-07 — What if they vomit after taking it?

Established. If the person throws up after taking the pill, write down when they took it and when they threw up. Do not give another pill until a pharmacist says what to do. The label gives no rule for repeat doses. During major surgery or a bad illness with much fluid loss, the doctor may pause this drug because muscle harm can hurt the kidneys. A mild illness does not mean the drug must stop. Call the doctor or pharmacist for advice.

Sources: Crestor US prescribing information

Repair action: retained-and-expanded

caregiver-08 — Can it be split, crushed, or mixed with food?

Established. Crestor is a tablet taken by mouth. The label does not provide instructions for crushing it, mixing it with food, or putting it through a feeding tube. Do not crush or split a tablet unless the pharmacist confirms the exact product and method. Ask about swallowing help or another plan before changing it. The tablet strength and the person's prescribed dose still matter. Keep the pharmacy's directions with the medicine so another caregiver does not use a different method.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

caregiver-10 — How should a liquid dose be measured?

Established. Crestor comes as tablets; its label does not say how to measure a liquid. If the person has a separate rosuvastatin liquid, follow that product’s label and use its stated strength. Ask the pharmacist to show you the right mark on the oral syringe, then show the dose back. Never turn a tablet dose in milligrams into milliliters; liquid strengths can differ. Keep the liquid in its own labeled bottle. Use the measuring tool supplied or advised for that exact product.

Sources: Crestor US prescribing information; MedlinePlus: Rosuvastatin

Repair action: replaced-raw-not-applicable

caregiver-11 — How can I help with an inhaler or other device?

Established. Crestor is a tablet, not an inhaler or injection device. Swallow it with or without food. The label gives no method for crushing it or giving it through a tube, so ask the pharmacist before changing how it is taken. Other rosuvastatin products may have different instructions; check that product's own label. Keep the bottle and check the strength before each dose. Ask the person to show how they take it and when they would call about muscle pain or weakness.

Sources: Crestor US prescribing information; MedlinePlus: Rosuvastatin

Repair action: replaced-raw-not-applicable

caregiver-13 — Which changes should I report promptly?

Established. Write down the rosuvastatin dose, missed doses, new medicines, muscle pain or weakness, dark urine, and test dates. Tell the care team about new muscle pain or weakness. Also report any new drug, mainly an antiviral or a drug that can raise muscle risk. Some drugs need a lower rosuvastatin dose or should not be used with it. Do not change the dose yourself. Bring the bottles or a current list to the visit so the pharmacist can check each drug.

Sources: Crestor US prescribing information; MedlinePlus: Rosuvastatin

Repair action: new-or-replaced-weak-answer

caregiver-17 — What should we record for the next appointment?

Established. Write down the rosuvastatin strength, when it is taken, missed doses, new medicines, muscle pain, and the next cholesterol test date. Bring the list and medicine bottle to the visit. Ask if the dose still fits the person's health and treatment goal. The person may feel no change when LDL falls, so looks and energy cannot show if it is working. Tell the care team about kidney or liver problems or trouble taking the tablet. Do not guess that the dose needs to change.

Sources: Crestor US prescribing information; MedlinePlus: Rosuvastatin

Repair action: new-or-replaced-weak-answer

caregiver-20 — How can I support the person’s choices?

Established. Ask what kind of help the person wants with rosuvastatin. They may prefer a reminder, help arranging refills, or support keeping track of blood tests. Explain that the medicine lowers LDL over time, even when they feel no different. Do not hide a tablet in food or force a dose. If the person is worried about muscle symptoms, cost, or whether treatment still matters, help them write questions for the pharmacist or prescriber. Respect their choice and make a plan with the care team.

Sources: MedlinePlus: Rosuvastatin; Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

Pharmacist

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

pharmacist-02 — Is the dose appropriate for this patient?

Established. Confirm indication, LDL goal, product, renal function, age, label dosing instructions and interacting drugs before assessing dose. The Crestor label starts Asian patients at 5 mg; severe renal impairment not on hemodialysis starts at 5 mg and is capped at 10 mg. Cyclosporine caps the dose at 5 mg. Avoid gemfibrozil if possible; if used, start at 5 mg and do not exceed 10 mg. Some antivirals must be avoided, while others have separate limits. CPIC suggests a start at 20 mg or less for poor SLCO1B1 or ABCG2 function; an optional 10 mg or less start applies with combined poor ABCG2 and reduced SLCO1B1. Use known genotypes, not ancestry.

Sources: Crestor US prescribing information; CPIC 2022 statin guideline

Repair action: new-or-replaced-weak-answer

pharmacist-04 — What adjustments apply in renal or hepatic impairment?

Established. For severe renal impairment (creatinine clearance below 30 mL/min/1.73 m²) without hemodialysis, Crestor starts at 5 mg once daily and must not exceed 10 mg. The label reports about threefold higher exposure in this group. It is contraindicated in acute liver failure or decompensated cirrhosis; chronic alcohol-related liver disease can raise exposure. Mild-to-moderate renal impairment does not cause the same concentration change. Assess kidney and liver status, dose, interacting drugs and muscle-risk factors together; do not transfer rules from another statin.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

pharmacist-06 — Which drug interactions are important?

Established. Rosuvastatin depends on OATP1B1 uptake and BCRP efflux; CYP3A4 is not a major clearance pathway. Cyclosporine raises exposure about sevenfold and limits Crestor to 5 mg daily; avoid gemfibrozil if possible, or start at 5 mg and cap at 10 mg. Avoid rosuvastatin with sofosbuvir/velpatasvir/voxilaprevir or ledipasvir/sofosbuvir. Separately, listed regimens such as simeprevir, glecaprevir/pibrentasvir and ritonavir combinations require a 5 mg start and 10 mg maximum. Check the exact label table and other lipid drugs for muscle risk.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

pharmacist-09 — What baseline and follow-up monitoring is needed?

Established. Obtain a lipid panel before treatment and again as clinically appropriate after initiation or dose adjustment; the label reports maximal LDL response by 4 weeks. Assess liver enzymes before starting and later when clinically indicated. Ask about muscle symptoms and risk factors, including renal impairment, age 65 or older, untreated hypothyroidism and interacting drugs. If persistent unexplained proteinuria or hematuria is found during routine testing, consider whether dose reduction is appropriate. The label does not require a universal monthly monitoring schedule.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

pharmacist-10 — What should counseling prioritize?

Established. Counsel that Crestor may be taken once daily with or without food at any time. Take it at least 2 hours before an aluminum/magnesium antacid. Explain that a blood test, not a felt sensation, measures LDL response; the full effect is generally present by 4 weeks. Review unexplained muscle pain, tenderness or weakness, especially with fever or feeling unwell. Ask about cyclosporine, gemfibrozil, antiviral therapy and supplements. For a known transporter genotype, use the CPIC row; do not infer genotype from ancestry.

Sources: Crestor US prescribing information; CPIC 2022 statin guideline

Repair action: new-or-replaced-weak-answer

pharmacist-12 — Can this product be crushed or given through a tube?

Uncertain. The US Crestor tablet label does not provide instructions for crushing a tablet or giving it through a feeding tube. Do not assume a tablet is suitable for crushing because it is not extended release. Check the exact maker, dosage form, tube location, flush plan and evidence for the proposed method with pharmacy references or the manufacturer. If a dose cannot be given as labeled, contact the prescriber for another plan. Document the method and monitoring rather than treating an unverified preparation as interchangeable.

Sources: Crestor US prescribing information

Repair action: retained-and-expanded

pharmacist-16 — What changes for children, older adults, or frailty?

Established. For children, the labeled indication and age determine whether rosuvastatin is appropriate: heterozygous familial hypercholesterolemia starts at age 8, while homozygous familial hypercholesterolemia starts at age 7. Pediatric doses differ by diagnosis and age. In older adults, the label notes no overall effectiveness or safety difference but identifies age 65 or older as a myopathy risk factor. Review renal and hepatic function, interacting drugs, dose and muscle symptoms rather than using age alone to lower or raise the dose.

Sources: Crestor US prescribing information

Repair action: retained-and-expanded

pharmacist-20 — How can the regimen be simplified?

Established. Crestor is already taken once daily, so simplification usually means connecting it with a routine and preventing refill gaps. Check for duplicate rosuvastatin products under brand and generic names, confirm strength, and remove unintended duplication. Review the exact tablet if swallowing or tube administration is raised; the label does not give a crushing method. Check interactions before aligning it with other medicines. Do not alternate statins or skip days to simplify without a prescriber-approved plan.

Sources: Crestor US prescribing information; MedlinePlus: Rosuvastatin

Repair action: retained-and-expanded

Clinician

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

clinician-01 — Where does this drug fit in treatment?

Established. Rosuvastatin is an LDL-lowering statin used for dyslipidemia and reduction of cardiovascular risk in labeled populations. The 2026 US dyslipidemia guideline supersedes the 2018 guideline; use its current risk framework and LDL goals rather than presenting the older intensity table as current guidance. The label's week-6 dose-response table reports LDL-C reductions of 45%, 52%, 55% and 63% at 5, 10, 20 and 40 mg. Select treatment by baseline risk, expected benefit, tolerance, interactions and patient preference; LDL lowering is a surrogate, while outcome evidence is population-specific.

Sources: 2026 US dyslipidemia guideline; Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

clinician-03 — How does it compare with alternatives?

Established. Against placebo, JUPITER supports primary prevention in selected adults without known cardiovascular disease who had LDL-C below 130 mg/dL and hsCRP at least 2 mg/L. Rosuvastatin 20 mg reduced the primary composite, but absolute benefit depends on baseline risk and follow-up. Alternatives include atorvastatin and, when LDL goals remain unmet, adding ezetimibe under current risk-based guidance. The 2026 US dyslipidemia guideline supersedes the 2018 framework. CTT supports a statin-class relationship between LDL reduction and vascular events, not equal absolute benefit for every patient or superiority over all alternatives.

Sources: Crestor US prescribing information; JUPITER trial; 2026 US dyslipidemia guideline; CTT 2010 meta-analysis

Repair action: new-or-replaced-weak-answer

clinician-04 — How large is the absolute clinical benefit?

Established. JUPITER randomized 8,901 participants per arm. The primary composite occurred in 142 rosuvastatin recipients and 252 placebo recipients: crude risks were 1.60% and 2.83%, an absolute difference of 1.24 percentage points. The reciprocal is 80.9, giving an NNT of 81 by upward rounding. The original paper reports median follow-up of 1.9 years; the label reports mean follow-up of 2 years. The trial stopped early for efficacy, and its selected population and composite endpoint limit transportability. This count-based estimate is not a universal individual forecast.

Sources: Crestor US prescribing information; JUPITER trial

Repair action: new-or-replaced-weak-answer

clinician-07 — What starting dose and titration are labeled?

Established. The adult labeled Crestor range is 5 to 40 mg once daily. Dose choice depends on indication, LDL-C and cardiovascular risk; do not assume one universal starting dose. Asian patients start at 5 mg. Severe renal impairment without hemodialysis starts at 5 mg and is capped at 10 mg. Cyclosporine caps the dose at 5 mg; avoid gemfibrozil or start at 5 mg and cap at 10 mg if needed. Avoid use with specific antiviral combinations. The label reports maximal LDL response by 4 weeks. Recheck lipids as appropriate.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

clinician-11 — Which outcomes and tests should be monitored?

Established. Follow LDL-C to assess the lipid response; the label reports maximal response by 4 weeks. That surrogate does not itself establish an individual reduction in myocardial infarction or stroke. In JUPITER, outcome evidence came from a selected primary-prevention population, with a composite endpoint and early stopping. Choose follow-up based on the treatment decision, adherence, tolerability and current guideline goals. Assess liver enzymes before treatment and later when clinically indicated, and evaluate muscle symptoms or interacting drugs rather than ordering tests on an unsupported fixed schedule.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

clinician-13 — How do comorbidities affect the choice?

Established. Renal impairment, age 65 or older, untreated hypothyroidism and interacting medicines increase muscle-injury concern. Severe renal impairment without hemodialysis requires a 5 mg start and 10 mg maximum. The label recommends a 5 mg start in Asian patients because median exposure was about twofold higher in pharmacokinetic studies; this is a population-level label instruction, not a substitute for genotype. CPIC provides genotype-specific recommendations for known SLCO1B1 and ABCG2 results. Balance expected LDL benefit against these risks and patient preferences, and check the exact interacting product.

Sources: Crestor US prescribing information; CPIC 2022 statin guideline

Repair action: retained-and-expanded

clinician-15 — Which interactions change management?

Established. Review interactions through transporter exposure and muscle-risk effects. Rosuvastatin is a substrate of OATP1B1 and BCRP; cyclosporine markedly raises exposure and caps dosing at 5 mg daily. Avoid gemfibrozil or, if use cannot be avoided, start at 5 mg and cap at 10 mg. Avoid rosuvastatin with sofosbuvir/velpatasvir/voxilaprevir or ledipasvir/sofosbuvir. Separately, regimens including simeprevir, glecaprevir/pibrentasvir and ritonavir combinations call for a 5 mg start and 10 mg maximum. Verify the exact agent and regimen.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

clinician-18 — When should treatment be switched or stopped?

Established. Consider switching or adding therapy when the patient’s LDL response, tolerance, risk and agreed goal have been reviewed. The Crestor label supports dose adjustment based on response and goal, with maximal LDL effect generally by 4 weeks. Confirm adherence, product, interactions and secondary contributors before calling treatment failure. Current 2026 US guidance should frame risk and LDL goals; historical 2018 thresholds are not current recommendations. If muscle symptoms occur, assess severity and competing causes rather than assuming every symptom is statin-caused or continuing a suspected severe reaction without evaluation.

Sources: Crestor US prescribing information; MedlinePlus: Rosuvastatin; 2026 US dyslipidemia guideline

Repair action: new-or-replaced-weak-answer

Nurse

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

nurse-02 — What should I check before administration?

Established. Before giving rosuvastatin, confirm the person, tablet strength, prescribed dose, allergies, recent changes and known interaction alerts. Ask about new muscle pain, tenderness or weakness, especially with fever or feeling unwell. Check whether a dose limit applies for severe kidney impairment, cyclosporine, gemfibrozil or antiviral therapy. The tablet may be given with or without food. Do not create a bedside hold rule from a single cholesterol result; clarify an order that conflicts with the current label or medication record.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

nurse-03 — Which vital signs and laboratory results matter?

Established. LDL cholesterol is the main lab used to assess rosuvastatin response; the label says the effect is usually maximal by 4 weeks. Liver enzymes are checked before treatment and later when clinically indicated. Ask about muscle pain or weakness, since severe muscle injury can affect the kidneys. At 40 mg, the label reports more urine protein or blood in some patients; follow the clinician's assessment and local protocol for abnormal urine findings. There is no routine blood-pressure target for this lipid medicine. Document the result and who will review it.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

nurse-04 — When should I clarify or hold a dose?

Established. Clarify an order when the listed dose exceeds a label limit for severe renal impairment, cyclosporine, gemfibrozil or a specific antiviral regimen. Escalate unexplained muscle pain, tenderness or weakness, especially with malaise or fever; suspected myopathy may require stopping under the prescriber's direction. The US label does not define a universal nursing hold threshold for every symptom or lab result. Verify the actual product and order, document the concern, and follow local escalation policy rather than changing a chronic medicine independently.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

nurse-06 — Does timing with food or medicines matter?

Established. Rosuvastatin is taken once daily and may be administered with or without food, at any time of day. Confirm the prescribed tablet and dose. Before administration, check for a newly added interacting medicine and ask about muscle pain or weakness. Aluminum- and magnesium-containing antacids can lower rosuvastatin exposure; the label instructs administration at least 2 hours before the antacid. If timing is unclear or the patient uses a different antacid product, ask pharmacy to confirm the plan. Record missed or delayed doses without doubling the next dose.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

nurse-07 — Are dilution, infusion, or compatibility checks relevant?

Established. Crestor is a tablet swallowed by mouth, not an IV product. Dilution, infusion-rate and line-compatibility checks do not apply. Verify the oral dose, tablet strength and timing. If a feeding tube is involved, ask pharmacy before changing how the tablet is given; the US label does not give a crushing or tube method. Document that IV preparation checks are out of scope for this product and follow the medication record for oral administration.

Sources: Crestor US prescribing information

Repair action: replaced-raw-not-applicable

nurse-10 — Which observations show benefit?

Established. A lipid panel shows the measurable response to rosuvastatin; the person may not feel LDL levels change. The label reports maximal effect by 4 weeks. Record when treatment began or changed, the dose, adherence concerns, and who will review the next result. Ask about muscle symptoms and new interacting medicines. A single improved value does not mean preventive treatment should stop. Do not use pulse or blood pressure as a substitute for lipid monitoring.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

nurse-12 — What requires immediate escalation?

Established. Seek urgent clinical assessment for severe unexplained muscle pain or weakness, especially with fever, malaise or dark urine, because rhabdomyolysis can injure the kidneys. Report signs of serious liver injury, such as jaundice or unusual severe fatigue, through the local escalation process. The label does not make every mild ache an emergency; document onset, severity, associated symptoms and interacting medicines. Follow the prescribed escalation pathway and do not advise a patient to restart or change the dose without the prescriber.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

nurse-18 — What should teach-back check?

Established. Ask the patient to explain that rosuvastatin lowers LDL over time and that a blood test checks the effect. Have them name their dose, daily routine and next test plan. Confirm they will report unexplained muscle pain, weakness or dark urine and tell the care team about new medicines. Review that the tablet can be taken with or without food and that some antacids need spacing. Ask the patient to repeat what they will do if a dose is missed; correct the plan using their prescription and pharmacist instructions.

Sources: Crestor US prescribing information; MedlinePlus: Rosuvastatin

Repair action: new-or-replaced-weak-answer

Student

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

student-03 — What is the mechanism of action?

Established. Rosuvastatin inhibits hepatic HMG-CoA reductase, lowering mevalonate and hepatic cholesterol. Reduced cholesterol activates SCAP–SREBP2 processing, increasing LDL-receptor expression and hepatic LDL uptake. Lower plasma LDL-C is a downstream pharmacodynamic result, not the same as target engagement; the label reports dose-dependent reductions by week 6. Its polar structure and OATP1B1 uptake/BCRP efflux contribute to disposition. Limited CYP3A4 metabolism differs from atorvastatin, but hydrophilicity does not prevent muscle toxicity; exposure, transporters, dose and patient factors still matter.

Sources: Crestor US prescribing information; Istvan and Deisenhofer 2001; SCAP/SREBP review

Repair action: new-or-replaced-weak-answer

student-04 — How does target action lead to benefit?

Established. Inhibiting hepatic HMG-CoA reductase reduces cholesterol synthesis, which increases LDL-receptor activity and clears more LDL particles from plasma. Rosuvastatin’s label reports about 45% LDL-C reduction at 5 mg and 63% at 40 mg in a six-week dose-response study. Clinical outcome benefit is a separate question: randomized trials and meta-analysis connect LDL lowering with fewer vascular events in studied populations. A biomarker response does not guarantee the same absolute event reduction for every person. Keep enzyme inhibition, LDL change and clinical outcomes as distinct steps in the causal chain.

Sources: Crestor US prescribing information; CTT 2010 meta-analysis

Repair action: new-or-replaced-weak-answer

student-05 — How is it absorbed, distributed, metabolized, and eliminated?

Established. Rosuvastatin has about 20% oral bioavailability and reaches peak plasma concentration in 3–5 hours. It is 88% protein bound and has a half-life near 19 hours. Only about 10% of a radiolabeled dose is recovered as metabolites; CYP2C9 forms the less potent N-desmethyl metabolite. Parent drug accounts for more than 90% of plasma inhibitory activity. Most dose-related material is excreted in feces. These pharmacokinetic measures do not equal LDL-response timing: the label says maximal LDL reduction is usually reached by 4 weeks.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

student-07 — What does its half-life mean clinically?

Established. A roughly 19-hour plasma half-life supports once-daily dosing, but it does not predict when LDL will reach its lowest treatment level. Rosuvastatin plasma peaks in 3–5 hours, while the label reports maximal LDL response by 4 weeks. Enzyme inhibition changes liver cholesterol and LDL-receptor handling over time. Separate concentration-time pharmacokinetics from a downstream lipid measurement. A drug can remain present for hours while the physiologic response develops over days or weeks.

Sources: Crestor US prescribing information

Repair action: retained-and-expanded

student-10 — Which adverse effects follow from its pharmacology?

Established. Lowering liver cholesterol can raise LDL-receptor expression and reduce LDL in blood, which explains the intended effect. Muscle injury risk has several contributors, including high exposure, high dose, kidney impairment, low thyroid function and interacting medicines. Rosuvastatin uses OATP1B1 and BCRP transporters, so a transporter inhibitor can raise exposure even though CYP3A4 metabolism is limited. Statin trials also show a small increase in new diabetes diagnoses. Explain this as a risk, not a prediction that one person will develop a side effect.

Sources: Crestor US prescribing information; Sattar et al. 2010 statin/diabetes meta-analysis

Repair action: retained-and-expanded

student-15 — How does it differ from related drugs?

Established. Rosuvastatin is more dependent on OATP1B1 uptake and BCRP efflux than on CYP3A4 metabolism. Atorvastatin has greater CYP3A4 involvement, so the interaction patterns differ; neither statin is interaction-free. Rosuvastatin’s label recommends a 5 mg start in Asian patients because studies found about twofold median exposure versus White controls. That label direction is not a genetic test. CPIC recommendations apply to known SLCO1B1 and ABCG2 genotypes and should not be assigned from ancestry alone.

Sources: Crestor US prescribing information; CPIC 2022 statin guideline; Atorvastatin US prescribing information

Repair action: new-or-replaced-weak-answer

student-19 — What evidence established its clinical role?

Established. Clinical evidence includes JUPITER, which studied selected adults without known cardiovascular disease who had elevated hsCRP, and statin meta-analyses such as CTT. JUPITER’s primary composite occurred in 142 of 8,901 rosuvastatin participants and 252 of 8,901 placebo participants; follow-up and selection shape the absolute effect. CTT supports proportional vascular risk reduction with LDL lowering across statin trials. Neither source proves identical benefit across all patients, endpoints or doses. Check design, comparator, baseline risk and early stopping before applying the result.

Sources: Crestor US prescribing information; JUPITER trial; CTT 2010 meta-analysis

Repair action: new-or-replaced-weak-answer

student-20 — What misconception should I avoid?

Established. Avoid saying that rosuvastatin dissolves plaque or cures high cholesterol. It inhibits HMG-CoA reductase in the liver, which lowers LDL in blood and reduces cardiovascular events in studied groups. The lipid response is measurable over weeks; prevention benefit is inferred from outcome trials over longer follow-up. The label’s JUPITER result was a composite endpoint in a selected primary-prevention population and the trial stopped early. Distinguish a drug’s mechanism, change in a risk marker and evidence for fewer clinical events.

Sources: Crestor US prescribing information; CTT 2010 meta-analysis

Repair action: new-or-replaced-weak-answer

Scientist

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

scientist-01 — What is the primary target and its evidence base?

Established. HMG-CoA reductase is the direct pharmacologic target. Evidence spans an experimental human catalytic-domain complex with rosuvastatin (PDB 1HWL), recombinant-enzyme inhibition and human LDL-C response. The structure supports a substrate-site binding mode; enzyme studies characterize inhibition under defined assay conditions. Label pharmacodynamics show dose-dependent LDL reduction. These layers support target engagement and translation, but a crystal structure alone does not establish in-vivo occupancy, tissue selectivity or outcome benefit. A complete causal chain also requires cellular feedback, exposure and clinical endpoint evidence.

Sources: Crestor US prescribing information; Istvan and Deisenhofer 2001; RCSB PDB 1HWL; Holdgate et al. 2003

Repair action: new-or-replaced-weak-answer

scientist-02 — Is the proposed mechanism causal or associated?

Established. Evidence that rosuvastatin acts through HMG-CoA reductase is supported by direct enzyme inhibition, a ligand-bound human catalytic-domain structure and downstream LDL-C reduction. The causal claim is stronger than an association, though each layer has limits: purified enzyme omits transport and feedback, while LDL change is a downstream biomarker. Randomized outcome trials and statin meta-analysis support clinical benefit through LDL lowering in defined groups. They do not identify every non-LDL pathway. Separate target binding, cellular response and patient outcome when evaluating a proposed additional mechanism.

Sources: Crestor US prescribing information; Istvan and Deisenhofer 2001; CTT 2010 meta-analysis

Repair action: new-or-replaced-weak-answer

scientist-03 — How can target engagement be measured?

Established. Biochemical HMG-CoA reductase inhibition and cellular sterol synthesis are proximal readouts; LDL-receptor expression and plasma LDL-C are downstream pharmacodynamic measures. PDB 1HWL provides a structural ligand pose, not a live-cell occupancy assay. In cells, transporter expression and compound exposure affect response; confirm viability and free concentration. A dose-response with orthogonal readouts can distinguish enzyme inhibition from nonspecific toxicity. Human LDL response supports pharmacodynamic activity, but it does not directly quantify liver target occupancy.

Sources: Crestor US prescribing information; RCSB PDB 1HWL; Istvan and Deisenhofer 2001

Repair action: new-or-replaced-weak-answer

scientist-06 — What tissue exposures are known?

Uncertain. Rosuvastatin disposition depends on hepatic OATP1B1 uptake and BCRP efflux, with limited CYP metabolism. The label and pharmacogenetic literature identify SLCO1B1 and ABCG2 variation as contributors to exposure differences. CPIC recommendations apply to patients with known genotypes; they are not a universal screening mandate. The cited label and studies do not establish quantitative rosuvastatin concentrations across human tissues. A tissue-distribution experiment could test that question, while separating tissue concentration from plasma exposure, transporter function and LDL response.

Sources: Crestor US prescribing information; CPIC 2022 statin guideline; Lee et al. 2005

Repair action: new-or-replaced-weak-answer

scientist-09 — How does response vary across biological contexts?

Established. Response can vary with baseline LDL, dose, adherence, hepatic function, kidney function, transporter genotype, interacting medicines and biological context. The label describes increased exposure with severe renal impairment and transporter inhibition; CPIC addresses known SLCO1B1 and ABCG2 genotypes. These variables can alter concentration or response, but they do not yield a precise individual forecast without a validated model. Stratify analyses by baseline risk and exposure, and avoid treating ancestry as a genotype or using a single lipid value as evidence of resistance.

Sources: Crestor US prescribing information; CPIC 2022 statin guideline

Repair action: new-or-replaced-weak-answer

scientist-12 — Have key findings been independently reproduced?

Established. Independent evidence supports different parts of rosuvastatin’s mechanism: structural work shows a bound human enzyme complex, recombinant-enzyme studies test inhibition, and JUPITER measures clinical outcomes. These are complementary results, not exact replications of one assay or one population. CTT supports a broader statin-class relationship between LDL lowering and vascular events. A future replication should prespecify enzyme conditions, cell exposure, lipid endpoints and clinical population; a structure or LDL response alone cannot reproduce an outcome claim.

Sources: Crestor US prescribing information; RCSB PDB 1HWL; Istvan and Deisenhofer 2001; Holdgate et al. 2003; JUPITER trial; CTT 2010 meta-analysis

Repair action: new-or-replaced-weak-answer

scientist-15 — Which biomarkers track engagement or response?

Established. Clinical biomarkers include LDL-C and apolipoproteins; JUPITER also selected participants using hsCRP, an inflammatory risk marker. The Crestor label reports a primary composite event reduction in that selected group, while CTT meta-analysis relates LDL lowering to vascular outcomes across trials. A biomarker may track response without proving it mediates every benefit. Prespecify the marker, outcome and causal question, and avoid equating hsCRP eligibility with a validated rosuvastatin target-engagement assay. The trial’s early stop and composite endpoint also matter when interpreting effect size.

Sources: Crestor US prescribing information; JUPITER trial; CTT 2010 meta-analysis

Repair action: new-or-replaced-weak-answer

scientist-19 — What negative or conflicting evidence matters?

Established. GISSI-HF tested rosuvastatin 10 mg in 4,574 people with chronic NYHA class II–IV heart failure. Death occurred in 657 of 2,285 treated participants and 644 of 2,289 on placebo; the adjusted hazard ratio was 1.00. Death or cardiovascular admission was also not reduced. This null result applies to that heart-failure population and does not contradict JUPITER’s selected primary-prevention finding or the broader statin evidence. It is not a reason for a patient to stop treatment without clinical advice.

Sources: GISSI-HF trial; JUPITER trial; CTT 2010 meta-analysis

Repair action: new-or-replaced-weak-answer

Chemist

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

chemist-01 — What is the structure and active molecular form?

Established. Crestor contains rosuvastatin calcium; the active rosuvastatin structure is stereodefined and includes a dihydroxy acid region, a pyrimidine ring and an N-methyl methanesulfonamide group. The label describes the calcium salt as a white amorphous powder. Tablet strength is expressed as rosuvastatin. PDB 1HWL contains rosuvastatin bound to a human HMG-CoA reductase catalytic fragment. The structure supports a binding pose, but the crystal does not establish formulation performance or comparative clinical potency.

Sources: Crestor US prescribing information; RCSB PDB 1HWL

Repair action: new-or-replaced-weak-answer

chemist-02 — Which functional groups matter for activity?

Established. The dihydroxy acid region of rosuvastatin mimics key features of the HMG-CoA reductase substrate/intermediate and occupies the enzyme’s substrate pocket. The pyrimidine and methanesulfonamide substituents add polar interactions in the binding site. The rosuvastatin complex is deposited as PDB 1HWL. These observations support a specific bound pose, not a complete quantitative structure–activity relationship. Contact geometry in one engineered catalytic construct cannot alone predict cell exposure, selectivity, or cardiovascular benefit.

Sources: RCSB PDB 1HWL; Istvan and Deisenhofer 2001

Repair action: new-or-replaced-weak-answer

chemist-05 — What supports the proposed binding mode?

Established. PDB 1HWL is an experimental human HMG-CoA reductase catalytic-fragment complex with rosuvastatin, reported at 2.10 Å resolution. It supports the bound orientation in the enzyme’s substrate region. The entry uses an engineered construct and a crystallographic ligand model; it is not a full-length membrane protein or a cellular exposure measurement. Use the structure to discuss binding-site contacts and pose, not clinical potency, enzyme-binding residence time, or tissue selectivity without separate evidence.

Sources: RCSB PDB 1HWL; Istvan and Deisenhofer 2001

Repair action: new-or-replaced-weak-answer

chemist-07 — How do ionization and pKa affect behavior?

Uncertain. The Crestor label identifies rosuvastatin calcium and gives product information, but it does not provide a validated pKa dataset for arbitrary solvent, temperature or ionic-strength conditions. Do not infer pKa from a partition coefficient or salt name. A formulation or assay decision needs a primary physicochemical source or direct measurement under specified conditions. Report solvent, temperature, ionic strength, method and whether the value is experimental or predicted. No numeric pKa is asserted here because the needed conditions and source were not verified.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

chemist-10 — Which transporters influence disposition?

Established. Rosuvastatin is a substrate of hepatic OATP1B1 uptake and BCRP efflux transporters. Inhibiting these transporters can increase systemic exposure and muscle-risk concern even though CYP3A4 is not a major metabolic route. The label gives agent-specific restrictions, including a 5 mg ceiling with cyclosporine and a 10 mg ceiling with gemfibrozil if use cannot be avoided. SLCO1B1 and ABCG2 genotype guidance is separate from drug-interaction management. Transporter status alone does not predict a patient’s dose.

Sources: Crestor US prescribing information; CPIC 2022 statin guideline

Repair action: new-or-replaced-weak-answer

chemist-11 — What are the main metabolic pathways?

Established. Rosuvastatin is not extensively metabolized. The label identifies N-desmethyl rosuvastatin, formed mainly by CYP2C9, as its principal metabolite. This metabolite has lower HMG-CoA reductase inhibitory activity than parent drug, and parent accounts for more than 90% of circulating inhibitory activity. The label reports that about 10% of a radiolabeled dose is recovered as metabolites. Limited metabolism does not remove interaction risk because transporter-mediated uptake and efflux still matter. Do not infer a full metabolite map from this summary.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

chemist-12 — Are metabolites active, reactive, or toxic?

Established. The label reports that N-desmethyl rosuvastatin has about one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent in vitro. More than 90% of active plasma inhibitory activity is attributed to parent rosuvastatin. This describes measured enzyme activity and plasma contribution, not a full reactive-metabolite toxicity map. A claim that a metabolite causes a clinical injury needs separate exposure and outcome evidence. Do not infer safety solely from a low metabolite fraction.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

chemist-13 — Which salt or solid-state form is used?

Established. Crestor tablets contain rosuvastatin calcium, while labeled strength is stated as rosuvastatin. The label describes rosuvastatin calcium as a white amorphous powder. This confirms the salt form for the branded tablet but does not map all polymorphs, hydrates or solid forms used by every generic manufacturer. A formulation comparison needs product-specific solid-state characterization, dissolution and stability data. Do not assume that a shared active ingredient establishes identical excipients or physical properties.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

Investor / Diligence Analyst

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

analyst-03 — How large is the reachable patient market?

Established. ClinCalc estimates 53.7 million US rosuvastatin prescriptions and 14.4 million patients in 2024, ranking it ninth by prescription volume. These MEPS-derived counts signal utilization, not unique eligible patients, sales, revenue or addressable market. A market model needs a defined indication, geography, payer coverage, net price, competitor set and overlap with other statins. Use the historical count as one input, state its date and method, and build the eligible population separately. Do not multiply prescriptions by a current retail price to infer company revenue.

Sources: ClinCalc 2024 utilization estimate; Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

analyst-05 — What meaningful differentiation is demonstrated?

Established. Rosuvastatin’s evidence-backed differentiation includes dose-dependent LDL reduction, transporter-driven disposition and limited CYP3A4 metabolism. The label’s dose-response table reports reductions from 45% at 5 mg to 63% at 40 mg at week 6. This is not proof of better outcomes than every competing statin at equivalent LDL reduction. Current commercial diligence should compare product, dose, guideline position, interactions, generic alternatives, adherence and net cost. Pharmacogenomic guidance is for known transporter genotypes; it does not establish a broad testing market or ancestry-based segmentation.

Sources: Crestor US prescribing information; CPIC 2022 statin guideline

Repair action: new-or-replaced-weak-answer

analyst-06 — How strong is the human efficacy evidence?

Established. JUPITER randomized 8,901 participants per arm and recorded 142 primary events with rosuvastatin versus 252 with placebo. The count-based absolute difference was about 1.24 percentage points; the original publication reports median 1.9-year follow-up and the label mean 2 years. This supports benefit in a selected prevention population, not a universal treatment effect. CTT provides broader statin-class outcome evidence. Diligence should retain comparator, population, endpoint and follow-up, and avoid treating early stopping as proof of commercial differentiation.

Sources: JUPITER trial; CTT 2010 meta-analysis; Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

analyst-16 — What patents, exclusivity, and freedom-to-operate issues apply?

Uncertain. FDA records show a first generic rosuvastatin approval on April 29, 2016 (ANDA 079167); that date is an approval milestone, not proof of a launch date. It does not establish current patent, exclusivity or freedom-to-operate status for a proposed product. A dated review must check the exact formulation, process, indication, jurisdiction, Orange Book listings and patent records with qualified counsel. Current status remains unverified here, and this FAQ is not a legal opinion.

Sources: Crestor US prescribing information; FDA first generic approvals, 2016; FDA Orange Book

Repair action: new-or-replaced-weak-answer

analyst-12 — What are the next decisive development milestones?

Uncertain. Rosuvastatin is an established approved medicine, but this review has not selected a new sponsor program or indication. A development milestone plan must name the product, target population, jurisdiction, evidence gap and regulatory route. Historical JUPITER results do not set a readout date for a new formulation or use. Before forecasting, request a target product profile, study design, manufacturing plan and agency strategy. No milestone date is supplied because those program choices and source documents are not available here.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

analyst-15 — What capital and time would the next milestone require?

Uncertain. A budget for a new rosuvastatin program depends on whether it is a generic product, a new formulation or a new indication. The existing label does not give trial, manufacturing or regulatory costs. Request a protocol, sample-size rationale, stability plan, jurisdiction, vendor quotes and sponsor assumptions before assigning money or time. Stage the estimate by decision points and include contingency. No cost or timeline is supplied here because no sponsor program or execution plan has been defined.

Sources: Crestor US prescribing information

Repair action: new-or-replaced-weak-answer

analyst-18 — What would support reimbursement and pricing?

Uncertain. Coverage and net price for a rosuvastatin product depend on the exact manufacturer, strength, payer and pharmacy channel. This review did not check current formularies, rebates, acquisition prices or patient cost sharing. A generic utilization count is not a reimbursement estimate. For a new product, show the added clinical or practical value over covered alternatives and define the payer group. Any price example needs a dated source, exact pack and included fees; the prior site snapshot expired and should not be reused.

Sources: Crestor US prescribing information; ClinCalc 2024 utilization estimate

Repair action: new-or-replaced-weak-answer

analyst-20 — What evidence would support real adoption?

Uncertain. Adoption would need evidence for the proposed product’s actual advantage, such as fewer cardiovascular events, safer use, easier dosing, better access or reliable supply. JUPITER supports an outcome claim only in its selected prevention population; it does not prove demand for a new formulation. Test the claim with a defined comparator, patient group, endpoint and access plan. Use interviews or real-world data to assess use barriers, then compare them with clinical evidence. This review has not measured demand or willingness to pay.

Sources: Crestor US prescribing information; JUPITER trial

Repair action: new-or-replaced-weak-answer

General

Questions for this perspective

1 drafted questions in this packet. Targeted additions or replacements for the current guide.

other-10 — How was it discovered?

Established. Rosuvastatin began as a new drug series at Shionogi, a company in Japan. In 1997, Watanabe and coauthors reported compound S-4522 as a candidate for more study. Later, the medicine became rosuvastatin, sold as Crestor. The US label lists its first approval in 2003. The early chemistry work showed how researchers chose a drug candidate; it did not prove that the medicine prevents heart attacks in people. Trials such as JUPITER studied that separate question.

Sources: Watanabe et al. 1997; Crestor US prescribing information; JUPITER trial

Repair action: new-or-replaced-weak-answer

[VERIFY: pKa values and ionization conditions need a source; quantitative human tissue concentrations remain unestablished in the cited evidence; confirm any sponsor program, capital plan, and milestones from founder records; current formularies, net prices, adoption, and market status need direct evidence; product-specific implementation, clinical review, and reader comprehension remain open. Generic-entry and current market conclusions are not inferred from utilization counts.]